Intranasal immunization with a flagellin-adjuvanted peptide anticancer vaccine prevents tumor development by enhancing specific cytotoxic T lymphocyte response in a mouse model.

Clin Exp Vaccine Res · 2013 · PMC3710921 · PMID 23858404

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Even though, the protection rate in peptide only group also remained marginally significant till 48 day, protection efficacy in P group was drastically decreased in long term observation.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.